MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-19-2026
Larimar Therapeutics Total Shareholders Equity 2011-2026 | LRMR
Annual Total Shareholders Equity Larimar Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 78.1 M | 172 M | 81.7 M | 111 M | 64.4 M | 89.7 M | -694 K | 93.3 M | 78.2 M | 122 M | 169 M | 104 M | -68.6 M | -54.7 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 172 M | -68.6 M | 74.2 M |
Quarterly Total Shareholders Equity Larimar Therapeutics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 139 M | 120 M | 144 M | 172 M | 198 M | 211 M | 231 M | 81.7 M | 92.7 M | 99.9 M | 106 M | 111 M | 119 M | 50.1 M | 57.1 M | 64.4 M | 72.1 M | 67.5 M | 78.8 M | 89.7 M | 89.7 M | 89.7 M | 89.7 M | -694 K | -694 K | -694 K | 53.6 M | 2.91 M | 93.3 M | 93.3 M | 93.3 M | 78.2 M | 78.2 M | 78.2 M | 78.2 M | 122 M | 122 M | 122 M | 122 M | 169 M | 169 M | 169 M | 169 M | 104 M | 104 M | 104 M | 104 M | -68.6 M | -68.6 M | -68.6 M | - | -54.7 M | - | - | - | -40.9 M | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 231 M | -68.6 M | 86.6 M |
Total Shareholders Equity of other stocks in the Biotechnology industry
| Issuer | Total Shareholders Equity | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Aquestive Therapeutics
AQST
|
-33.7 M | $ 4.12 | -0.36 % | $ 441 M |  USA |
 |
MorphoSys AG
MOR
|
621 M | - | 2.43 % | $ 254 M |  Germany |
 |
Arcturus Therapeutics Holdings
ARCT
|
214 M | $ 8.32 | 3.67 % | $ 228 M |  Israel |
 |
Arcutis Biotherapeutics
ARQT
|
189 M | $ 23.65 | 0.08 % | $ 3.01 B | USA |
 |
BioVie
BIVI
|
19 M | $ 1.46 | 2.82 % | $ 2.16 M | USA |
 |
BioLineRx Ltd.
BLRX
|
22 M | $ 2.32 | 4.98 % | $ 908 M | Israel |
 |
BioNTech SE
BNTX
|
1.37 B | $ 91.44 | 0.29 % | $ 27.2 B | Germany |
 |
I-Mab
IMAB
|
1.72 B | - | - | $ 866 M |  China |
 |
Genfit SA
GNFT
|
-16.2 M | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
2.27 M | - | -13.47 % | $ 169 M | France |
 |
BioXcel Therapeutics
BTAI
|
-95.5 M | $ 1.16 | -2.12 % | $ 14.2 M | USA |
 |
Midatech Pharma plc
MTP
|
6.72 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Burford Capital Limited
BUR
|
1.7 B | $ 4.52 | 9.18 % | $ 683 M | Britain |
 |
Acorda Therapeutics
ACOR
|
-158 M | - | -24.86 % | $ 820 K | USA |
 |
Cabaletta Bio
CABA
|
112 M | $ 3.1 | 4.56 % | $ 311 M | USA |
 |
Adverum Biotechnologies
ADVM
|
70.7 M | - | - | $ 86.2 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
5.44 M | $ 3.17 | 1.44 % | $ 6.9 B | Israel |
 |
Advaxis
ADXS
|
-24.4 M | - | -9.65 % | $ 45.9 M | USA |
|
Applied Molecular Transport
AMTI
|
60.8 M | - | - | $ 10.1 M | USA |
 |
AgeX Therapeutics
AGE
|
-37 K | - | -10.17 % | $ 12.2 K | USA |
 |
AIkido Pharma
AIKI
|
69.4 M | - | 1.93 % | $ 17.4 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
715 M | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
29.5 M | - | - | $ 26.5 M | USA |
 |
Akero Therapeutics
AKRO
|
750 M | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
234 M | - | 0.23 % | $ 488 M | USA |
 |
Catalyst Biosciences
CBIO
|
106 M | $ 19.48 | 0.39 % | $ 1.74 B | USA |
 |
Allena Pharmaceuticals
ALNA
|
18.9 M | - | 3.16 % | $ 1.9 M | USA |
 |
Codexis
CDXS
|
50.5 M | $ 1.95 | 6.87 % | $ 170 M | USA |
 |
Alpine Immune Sciences
ALPN
|
179 M | - | - | $ 2.17 B | USA |
 |
Aileron Therapeutics
ALRN
|
16.9 M | - | 10.36 % | $ 9.8 M | USA |
 |
Anavex Life Sciences Corp.
AVXL
|
94.9 M | $ 3.01 | 0.67 % | $ 257 M | USA |
 |
Cerus Corporation
CERS
|
64.2 M | $ 1.91 | 2.69 % | $ 364 M | USA |
 |
Cullinan Management
CGEM
|
409 M | $ 15.11 | 4.71 % | $ 910 M | USA |
 |
Coherus BioSciences
CHRS
|
61 M | $ 1.72 | -0.87 % | $ 201 M | USA |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
13.5 M | $ 0.46 | -13.02 % | $ 5.27 M | Israel |
 |
Aravive
ARAV
|
10.7 M | - | -13.39 % | $ 1.45 M | USA |
 |
Aptose Biosciences
APTO
|
-27.2 M | - | -45.71 % | $ 1.2 M |  Canada |
 |
Aptinyx
APTX
|
38.3 M | - | -39.0 % | $ 4.57 M | USA |
 |
CNS Pharmaceuticals
CNSP
|
4.52 M | $ 2.25 | -0.44 % | $ 998 K | USA |
 |
CureVac N.V.
CVAC
|
688 M | - | - | $ 867 M | Germany |
 |
AstraZeneca PLC
AZN
|
15.6 B | - | - | $ 96.9 B | Britain |
 |
Catalyst Pharmaceuticals
CPRX
|
954 M | $ 24.95 | 1.05 % | $ 3.05 B | USA |
 |
Celldex Therapeutics
CLDX
|
527 M | $ 31.33 | 0.85 % | $ 2.08 B | USA |
 |
Corbus Pharmaceuticals Holdings
CRBP
|
148 M | $ 10.27 | 0.98 % | $ 137 M | USA |
 |
Cardiff Oncology
CRDF
|
45.4 M | $ 1.6 | 1.27 % | $ 107 M | USA |
 |
Avenue Therapeutics
ATXI
|
1.83 M | - | -52.27 % | $ 4.45 M | USA |